These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2390749)

  • 1. "Disinformation" from pharmaceutical company representatives.
    Gordon M
    CMAJ; 1990 Sep; 143(5):370. PubMed ID: 2390749
    [No Abstract]   [Full Text] [Related]  

  • 2. "Disinformation" from pharmaceutical company representatives.
    Gordon M
    CMAJ; 1990 Jun; 142(11):1177-8. PubMed ID: 2344567
    [No Abstract]   [Full Text] [Related]  

  • 3. Biopharmaceutical benchmarks--2003.
    Walsh G
    Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 5. For appearance only.
    Wood G
    Am Pharm; 1989 Feb; NS29(2):5. PubMed ID: 2929420
    [No Abstract]   [Full Text] [Related]  

  • 6. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Grice S
    N Z Bioeth J; 2003 Oct; 4(3):22-4. PubMed ID: 15597479
    [No Abstract]   [Full Text] [Related]  

  • 7. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 8. Canada to allow production of generic AIDS drugs.
    Nat Rev Drug Discov; 2003 Nov; 2(11):854. PubMed ID: 14702955
    [No Abstract]   [Full Text] [Related]  

  • 9. QUAD routes out inferior drugs.
    Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
    [No Abstract]   [Full Text] [Related]  

  • 10. Polymorphism in generic drug product development.
    Snider DA; Addicks W; Owens W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):391-5. PubMed ID: 14962588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opinions of pharmacy, medicine, and pharmaceutical industry leaders about hypothetical therapeutic-interchange legislation.
    Segal R; Grines LL; Pathak DS
    Am J Hosp Pharm; 1988 Mar; 45(3):570-7. PubMed ID: 3369459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Woolner D
    N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481
    [No Abstract]   [Full Text] [Related]  

  • 13. Panel discussion: practical importance of generic equivalence.
    Ann Clin Res; 1974; 6(0):suppl 11:79-88. PubMed ID: 4212521
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical equivalency: a health protection branch perspective.
    Morrison AB; Cook D; Casselman WG
    Can Med Assoc J; 1973 Oct; 109(8):806-8. PubMed ID: 4746138
    [No Abstract]   [Full Text] [Related]  

  • 15. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Adams J
    N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
    [No Abstract]   [Full Text] [Related]  

  • 16. [The relative therapeutic value of drugs in international comparison: differences between Switzerland and Canada].
    Gysling E
    Schweiz Med Wochenschr; 1976 Nov; 106(46):1609-12. PubMed ID: 1013683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less expensive ZDV on the way.
    AIDS Read; 2005 Nov; 15(11):573-4. PubMed ID: 16329175
    [No Abstract]   [Full Text] [Related]  

  • 19. What information do physicians receive from pharmaceutical representatives?
    Lexchin J
    Can Fam Physician; 1997 May; 43():941-5. PubMed ID: 9154366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug substitution: remedy or rip-off?
    Goodman WE
    Can Med Assoc J; 1983 Jan; 128(2):198, 200-2. PubMed ID: 6848166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.